Jasper Therapeutics, Inc. (JSPR) Reports In-Line Q2 EPS

Jasper Therapeutics, Inc. (NASDAQ: JSPR) reported Q2 EPS of ($0.15), in-line with the analyst estimate of ($0.15).

For earnings history and earnings-related data on Jasper Therapeutics, Inc. (JSPR) click here.

You May Also Be Interested In

• Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
• PPL Corp. (PPL) Misses Q2 EPS by 4c
• Array Digital Infrastructure, Inc. (AD) Tops Q2 EPS by 345c